Titan Pharmaceuticals Inc
-0.0199 (-2.58%)


Draw Mode:

Volume 14,573
Bid Price 0.75
Ask Price 0.81
News (1)
Day High 0.77


52 Week Range


Day Low 0.75
Company Name Stock Ticker Symbol Market Type
Titan Pharmaceuticals Inc TTNP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0199 -2.58% 0.7501 18:50:51
Open Price Low Price High Price Close Price Prev Close
0.75 0.75 0.77 0.7501 0.77
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
93 14,573 $ 0.7607512 $ 11,086 - 0.3496 - 1.59
Last Trade Time Type Quantity Stock Price Currency
19:20:03 2 $ 0.75 USD

Titan Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 10.97M 14.63M 14.57M $ 1.53M $ - -0.90 14.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 57.50k 18.40%

more financials information »

Titan Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No TTNP Message Board. Create One! See More Posts on TTNP Message Board See More Message Board Posts

Historical TTNP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.800.8190.750.77872420,250-0.0499-6.24%
1 Month0.9680.99750.7360.861838120,245-0.2179-22.51%
3 Months0.791.090.7201010.916092631,193-0.0399-5.05%
6 Months1.251.250.7201010.934676532,033-0.4999-39.99%
1 Year1.031.590.34960.8403737243,536-0.2799-27.17%
3 Years6.6014.0640.34966.044,873,301-5.85-88.63%
5 Years234.00252.000.349614.214,730,222-233.25-99.68%

Titan Pharmaceuticals Description

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.